CATUG Biotechnology is a technology-driven CRDMO platform supporting nucleic acid and advanced therapeutics from early research to GMP-oriented CMC execution. Built around integrated capabilities in plasmid DNA, RNA drug substance, LNP/tLNP and novel delivery systems, protein/nanobody manufacturing, analytical development, and GMP manufacturing, CATUG helps global innovators translate complex therapeutic concepts into clinical-stage programs. Since its founding in 2021, CATUG has grown into a team of approximately 200 professionals and established R&D and GMP manufacturing capabilities to support complex therapeutic modalities across DNA, RNA, delivery systems, proteins, and advanced CMC workflows. Guided by our core values — Focus, First, Fast, and Flexible — CATUG provides both modular and end-to-end CMC solutions, connecting early innovation with scalable manufacturing, analytical control, quality systems, and regulatory-aligned documentation to accelerate clients’ programs toward clinical development and commercialization readiness.